Drugs / Oncoquest-CLL
Oncoquest-CLL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01976520 | Oct 2013 → Jan 2024 | B-cell chronic lymphocytic leukemia | XEME Biopharma Inc. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oncoquest-CLL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01976520 ↗ |
| Known as | ATCE Vaccine | “ATCE Vaccine, ATCEV, Autologous Tumor Vaccine, Oncoquest-CLL” NCT01976520 ↗ |
| Known as | ATCEV | “ATCE Vaccine, ATCEV, Autologous Tumor Vaccine, Oncoquest-CLL” NCT01976520 ↗ |
| Known as | Autologous Tumor Vaccine | “ATCE Vaccine, ATCEV, Autologous Tumor Vaccine, Oncoquest-CLL” NCT01976520 ↗ |
| Modality | Vaccine | “vaccine therapy” NCT01976520 ↗ |
| Route | Subcutaneous | “receive Oncoquest-CLL vaccine subcutaneously” NCT01976520 ↗ |